• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v2
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Business

August 14, 2015

CN Bio appoints Dr David Hughes to board of directors

Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing

Category iconBusiness

August 11, 2015

CN Bio Innovations features in Al Jazeera documentary “The Cure”

Welwyn Garden City, UK, 11 August 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms, was featured in the 10 August

Category iconBusiness

June 12, 2015

CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist

Welwyn Garden City, UK, 12 June 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for

Category iconBusiness

May 27, 2015

CN Bio Innovations announces LiverChip research study with leading pharmaceutical company

Welwyn Garden City, UK, 27th May 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics

Category iconBusiness

April 21, 2015

CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company

Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics

Category iconBusiness

March 19, 2015

CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals

CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased

Category iconBusiness

November 17, 2014

CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014

CN Bio Innovations’ (CN Bio) Investigator Meeting entitled “Hepatitis B: New models pave the way to a cure” was held on Monday 10th November 2014 at

Category iconBusiness

October 28, 2014

NIH Director highlights LiverChip in Compton Lecture

Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on

Category iconBusiness

September 17, 2014

TSB Funds New Research by CN Bio into Fatty Liver Disease

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development

Category iconBusiness

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling September 1, 2025
  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
Cyber Essentials Logo